Literature DB >> 16315337

Treatment with statins after acute myocardial infarction in patients >or=80 years: underuse despite general acceptance of drug therapy for secondary prevention.

Elena Kvan1, Kjell I Pettersen, Knud Landmark, Asmund Reikvam.   

Abstract

PURPOSE: It has not been decided to what extent the results from statin trials should be transferred to clinical practice in the very old. The aim of the study was to assess the use of cardiovascular drugs after an acute myocardial infarction (MI), with particular focus on statins, in very old patients as compared to younger patients.
METHOD: A sample of 901 acute MI patients was drawn from 16 hospitals in 1999/2000; the patients were followed up for 2.5 years. Information on demographic variables and drug therapy was obtained from hospital records, and in the follow-up period by direct patient contact or questionnaire. The main indications for prescribing the various cardiovascular drugs were recorded.
RESULTS: At discharge, drug use in patients >or=80 and <80 years, respectively, was as follows: ACE-inhibitors 48 versus 32%, nitrates 55 versus 32%, diuretics 64 versus 26%, aspirin 72 versus 86%, and beta-blockers 67 versus 85%. A striking difference was found for statins: 9% in the very old and 72% in younger patients. The pattern of drug use generally remained unchanged after 2.5 years. Survival rates for patients >or=80 and <80 years: at discharge 72 versus 90%, after 2.5 years 34 versus 73%.
CONCLUSIONS: Drug therapy was widely accepted for the indication secondary prevention after MI in patients above 80 years of age. The various cardiovascular drugs were prescribed to about the same extent for very old and younger patients. The exception was lipid lowering drugs which, despite the physicians' recognition of the indication secondary prevention in the very old patients, were prescribed to a limited extent. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16315337     DOI: 10.1002/pds.1172

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  10 in total

1.  Pharmacists' and pharmacy students' ability to identify drug-related problems using TIMER (Tool to Improve Medications in the Elderly via Review).

Authors:  Sarah Snyder Lee; Ann K Schwemm; Jeffrey Reist; Matthew Cantrell; Michael Andreski; William R Doucette; Elizabeth A Chrischilles; Karen B Farris
Journal:  Am J Pharm Educ       Date:  2009-05-27       Impact factor: 2.047

2.  Optimizing elderly pharmacotherapy: polypharmacy vs. undertreatment. Are these two concepts related?

Authors:  Encarnación Blanco-Reina; Gabriel Ariza-Zafra; Ricardo Ocaña-Riola; Matilde León-Ortíz; Inmaculada Bellido-Estévez
Journal:  Eur J Clin Pharmacol       Date:  2014-11-09       Impact factor: 2.953

3.  Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.

Authors:  Elizabeth A Chrischilles; Kathleen M Schneider; Mary C Schroeder; Elena Letuchy; Robert B Wallace; Jennifer G Robinson; John M Brooks
Journal:  J Am Geriatr Soc       Date:  2016-03-01       Impact factor: 5.562

4.  Potentially inappropriate prescribing in an Irish elderly population in primary care.

Authors:  Cristín Ryan; Denis O'Mahony; Julia Kennedy; Peter Weedle; Stephen Byrne
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

5.  Medical treatment predicts mortality after hip fracture.

Authors:  Vibeke Juliebø; Maria Krogseth; Eva Skovlund; Knut Engedal; Torgeir B Wyller
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-12-18       Impact factor: 6.053

6.  Use of health services and medicines amongst Australian war veterans: a comparison of young elderly, near centenarians and centenarians.

Authors:  Elizabeth E Roughead; Lisa M Kalisch; Emmae N Ramsay; Philip Ryan; Andrew L Gilbert
Journal:  BMC Geriatr       Date:  2010-11-04       Impact factor: 3.921

7.  Prognostic value of cardiovascular disease status: the Leiden 85-plus study.

Authors:  Petra G van Peet; Yvonne M Drewes; Anton J M de Craen; Rudi G J Westendorp; Jacobijn Gussekloo; Wouter de Ruijter
Journal:  Age (Dordr)       Date:  2012-07-04

8.  Potentially inappropriate prescribing in institutionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria.

Authors:  Amalia Ubeda; Luisa Ferrándiz; Nuria Maicas; Cristina Gomez; Montserrat Bonet; Jose E Peris
Journal:  Pharm Pract (Granada)       Date:  2012-06-30

9.  Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.

Authors:  Kuijing Wang; Bo Li; Yuanyuan Xie; Nan Xia; Minghui Li; Guang Gao
Journal:  Mol Med Rep       Date:  2020-06-23       Impact factor: 2.952

10.  Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.

Authors:  Ingeborg Hartz; Solveig Sakshaug; Kari Furu; Anders Engeland; Anne Elise Eggen; Inger Njølstad; Svetlana Skurtveit
Journal:  BMC Clin Pharmacol       Date:  2007-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.